On June 5, Shougang LanzaTech declined 7.71% in regular trading, trading at 31.82 HKD/share, with trading volume of approximately 30.70 million HKD.

The selloff is primarily driven by heavy profit-taking following the stock's explosive post-IPO rally. The company listed on the Hong Kong Stock Exchange on June 3 at an IPO price of 14.6 HKD/share, surged over 90% on its debut, and gained another 30%+ on the second day, accumulating nearly 100% in gains within just two sessions. The rapid price appreciation attracted substantial short-term speculative capital, which is now exiting positions.

Fundamental concerns further weigh on sentiment. The company has explicitly stated it does not expect to achieve net profit breakeven in the near term, projecting continued significant net losses. During the IPO process, institutional appetite was notably restrained — the international placement received only 0.95x subscription, a rare under-subscription scenario that contrasts starkly with the retail public offering's 1421x oversubscription. This divergence between institutional caution and retail exuberance highlights valuation digestion pressure following the sharp run-up.

Shougang LanzaTech, established in 2011, is the first company globally to commercialize and scale low-carbon product manufacturing using verified synthetic biology technology in the CCUS sector, operating four large-scale production facilities across China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)